| Median age (range) |
59 years (39-74) |
|
| Male |
12 (70.6%) |
|
| Prior systemic therapies |
|
| None |
9 (52.9%) |
| Adjuvant setting only |
3 (17.6%) |
| Sargramostim |
1 |
| Temozolomide |
1 |
| Dacarbazine, Cisplatin, Velban, Interleukin-2, Interferon α |
1 |
| Metastatic setting only |
3 (17.6%) |
| Temozolomide |
1 |
| Everolimus |
1 |
| Interleukin-2 |
1 |
| Both adjuvant and metastatic settings |
2 (11.8%) |
| Interferon α, then Interleukin-2 |
1 |
| Interferon α, then Sargramostim |
1 |
|
| ECOG performance status |
|
| 0 |
9 (52.9%) |
| 1 |
8 (47.1%) |
|
| Pre-existing signs and symptoms |
|
| Grade 1 neurosensory |
1 (5.9%) |
| Grade 1 musculoskeletal pain |
3 (17.6%) |
| Grade 1 arthralgia |
3 (17.6%) |
| Grade 2 arthralgia |
3 (17.6%) |
